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ABSTRACT
Objective Primary percutaneous coronary intervention
(PPCI) for ST-elevation myocardial infarction (STEMI) is
insufﬁciently implemented in many countries. We
investigated patient and hospital characteristics
associated with PPCI utilisation.
Methods Whole country registry data (MINAP,
Myocardial Ischaemia National Audit Project) comprising
PPCI-capable National Health Service trusts in England
(84 hospital trusts; 92 350 hospitalisations; 90 489
patients), 2003–2013. Multilevel Poisson regression
modelled the relationship between incidence rate ratios
(IRR) of PPCI and patient and trust-level factors.
Results Overall, standardised rates of PPCI increased
from 0.01% to 86.3% (2003–2013). While, on average,
there was a yearly increase in PPCI utilisation of 30%
(adjusted IRR 1.30, 95% CI 1.23 to 1.36), it varied
substantially between trusts. PPCI rates were lower for
patients with previous myocardial infarction (0.95, 0.93
to 0.98), heart failure (0.86, 0.81 to 0.92), angina
(0.96, 0.94 to 0.98), diabetes (0.97, 0.95 to 0.99),
chronic renal failure (0.89, 0.85 to 0.90),
cerebrovascular disease (0.96, 0.93 to 0.99), age
>80 years (0.87, 0.85 to 0.90), and travel distances
>30 km (0.95, 0.93 to 0.98). PPCI rates were higher for
patients with previous percutaneous coronary
intervention (1.09, 1.05 to 1.12) and among trusts with
>5 interventional cardiologists (1.30, 1.25 to 1.34),
more visiting interventional cardiologists (1–5: 1.31,
1.26 to 1.36; ≥6: 1.42, 1.35 to 1.49), and a 24 h,
7-days-a-week PPCI service (2.69, 2.58 to 2.81). Half of
the unexplained variation in PPCI rates was due to
between-trust differences.
Conclusions Following an 8 year implementation
phase, PPCI utilisation rates stabilised at 85%. However,
older and sicker patients were less likely to receive PPCI
and there remained between-trust variation in PPCI rates
not attributable to differences in stafﬁng levels.
Compliance with clinical pathways for STEMI is needed
to ensure more equitable quality of care.
INTRODUCTION
Variation between and within countries in the
adoption of evidence based care is a major global
healthcare problem.1 ST-elevation myocardial
infarction (STEMI) comprises 25–40% of all acute
myocardial infarction cases in Europe and the USA,
and represents one of the most common reasons
for hospitalisation worldwide.2–4 For its acute
management, there is a Class 1 Level A treatment
recommendation for primary percutaneous coron-
ary intervention (PPCI) because it is associated with
a relative risk reduction of death of approximately
37% over ﬁbrinolytic therapy.5 However, studies
report substantial inter-regional differences in its
utilisation.6–11 It is not surprising that strategies to
ensure its wider and faster diffusion have been at
the forefront of international efforts to improve the
quality and outcomes of cardiovascular care.
Thus far none of the studies investigating the dif-
fusion of PPCI have incorporated whole healthcare
systems or assessed patient-level and hospital-level
data simultaneously.8 9 12 Rather, they have been
based on small samples, select cohorts, span only
part of the implementation phase or have been
limited through their use of non-contemporaneous,
administrative or insurance-based databases.7 13–15
This is particularly important because convenience
sampling of only cases and centres with
up-to-standard data may bias estimates or create
uncertainty around the impact of clinical variables.
In addition, earlier studies typically have been eco-
logical in design—an approach which limits the
interpretation of inferences about outcomes relat-
ing to individuals.8 9 As a result, the literature pro-
vides an uncertain picture of the relationship
between patient-level and hospital-level character-
istics and the diffusion of PPCI. Many countries do
not yet provide PPCI as the treatment of choice for
the emergency reperfusion of STEMI.16–20
Contemporary knowledge about the barriers and
enablers of PPCI implementation will be essential
to the future effective provision of nationwide
services.
In the UK, continuous whole country data for
STEMI and associated PPCI are collected through
the Myocardial Ischaemia National Audit Project
(MINAP) registry. This provides a unique oppor-
tunity to undertake large-scale phenotype- and
intervention-speciﬁc research. To address the limita-
tions of previous studies, for a clinically important
cohort, we used MINAP data to investigate the dif-
fusion of PPCI for STEMI across the National
Health Service (NHS) in England. Speciﬁcally, the
aims of this study were (1) to describe between-
hospital and temporal variation in standardised
rates of utilisation of PPCI, and (2) to quantify
patient-level and trust-level factors associated with
its implementation.
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METHODS
Setting and design
Anonymised patient level data were obtained from the national
heart attack register, MINAP. MINAP is a comprehensive clinical
database of patients hospitalised with acute myocardial infarc-
tion, mandated by the Department of Health for all hospitals in
England and Wales.21 Data are collected prospectively at each
hospital, electronically encrypted and transferred online to a
central database. Data entry is subject to routine error checking
and a mandatory annual validation exercise. MINAP is overseen
by a multi-professional steering group and the National Institute
for Cardiovascular Outcomes Research (NICOR) executive.22
Each MINAP entry provides patient demographic data and clini-
cal details of the patient journey across 122 data items. NICOR,
which includes MINAP, has support under section 251 of the
NHS Act 2006 to use patient information for medical research
without consent (Ref: NIGB: ECC 1-06 (d)/2011). Ethical
approval was not required under NHS research governance
arrangements.
Individuals were eligible for inclusion in our study if they
were admitted directly to a PPCI-capable hospital (a hospital
with the infrastructure and skills to offer PPCI) in England with
STEMI between 1 January 2003 and 30 June 2013 and were
aged ≥18 years. Inter-hospital transfers were not included in the
analysis, nor hospitals performing only sporadic PPCI proce-
dures. STEMI diagnoses were identiﬁed via the discharge diag-
nosis as recorded in MINAP. Patient baseline characteristics were
age, gender, ethnicity, comorbidities, previous medical history,
and socioeconomic status (based on the 2010 English Indices of
Multiple Deprivation, and categorised from most deprived (5)
to least deprived (1)). Patients were selected as having received
PPCI according to their initial reperfusion strategy. To be eligible
for PPCI, patients met the following criteria: clinical presenta-
tion suggestive of myocardial infarction with symptom duration
of ≤12 h and ST-segment elevation of ≥0.1 mV in at least two
contiguous leads, or ≥0.2 mV in V1–V3, or presumed new-
onset left bundle branch block on electrocardiography.
The characteristics of hospitals for each year of study, includ-
ing number of interventional cardiologists, number of visiting
interventional cardiologists, type of PPCI service offered (‘24/7’
or ‘9 to 5’ service), teaching status, and hospital size (measured
as total number of hospital beds) were obtained from the British
Cardiovascular Intervention Society (BCIS) survey (personal
communication with PFL). In addition, publicly available hos-
pital trust data concerning the total available bed days and
number of occupied bed days by consultant main specialty were
obtained from NHS England (http://www.england.nhs.uk/
statistics/statistical-work-areas/bed-availability-and-occupancy/
bed-data-overnight/) from 2003 to 2013. Although these latter
data were not available for individual hospitals within a trust,
among our cohort of hospitals there were only three trusts
which contained more than one hospital providing PPCI ser-
vices (in these cases the trust characteristics were applied to
both hospitals). Euclidean (straight line) distances from each
patient’s residence to the nearest trust with onsite PPCI facilities
were derived from patients’ and trusts’ postcodes, translated
into Cartesian coordinates (see online supplementary appendix
section 1). All trust data were linked to MINAP data through
the NICOR analytical team before releasing pseudonymised
patient and hospital identiﬁcation data for the analyses.
Outcome
The primary endpoint was PPCI utilisation, calculated as the
rate of PPCI per hospital out of the total number of STEMI
hospitalisations per hospital. For patients with multiple PPCIs
across multiple hospitalisations, all were included in the
calculation.
Statistical analysis
Baseline characteristics were summarised as numbers and per-
centages, means and SDs, and medians and IQRs for categorical,
normally distributed and non-normally distributed continuous
data, respectively. To analyse temporal trends of PPCI utilisation,
age-and sex-standardised rates of PPCI per 100 000 STEMI hos-
pitalisations and 95% CIs were summarised by year of hospitali-
sation for PPCI.
We built a series of multilevel Poisson regression models
(which accounted for the clustering of patients within trusts) to
quantify the degree to which patient characteristics and
trust-level factors were associated with annual hospital PPCI
utilisation, with the number of STEMI hospitalisations as the
offset term. Initially, univariable models were ﬁtted and subse-
quently multivariable models built by incrementally adding vari-
ables which had signiﬁcant associations with PPCI utilisation to
a base model that comprised age, sex and year as well as a
random intercept for each trust. The Index of Multiple
Deprivation quintile did not contribute signiﬁcantly to the base
model and was, therefore, omitted. Initially models focused on
patient characteristics and then on trust-level characteristics to
assess their relative impact upon PPCI utilisation. Model
estimates were presented as incidence rate ratios (IRRs) which
are interpreted as the linear increase or decrease in trust PPCI
utilisation over the study period after adjusting for confounding
factors. All explanatory variables were introduced as ﬁxed
effects, except year, which was included as a random effect to
allow for variation in the rate of change of PPCI utilisation over
time between trusts. To assess the degree of variation in PPCI
utilisation rates attributed to the trust level (and not explained
by the model), we obtained an approximation to the intraclass
correlation coefﬁcient (ICC) from a multilevel linear regression
model which used PPCI rates as the outcome (see online supple-
mentary appendix section 1).
The extent of patients with missing data for case mix vari-
ables and confounders was evaluated and managed by multiple
imputation. To undertake this, we imputed 10 datasets using
chained equations before analysis and pooled estimates using
Rubin’s rules across the imputed datasets. Imputation models
were congruent to analysis models and included the outcome
variable following methods used previously for MINAP data
(see online supplementary appendix table S1). To check the
accuracy and consistency of the imputation process, imputed
data were compared to complete case analysis (see online sup-
plementary appendix table S2). The Poisson model was checked
for overdispersion by comparison with a negative binomial
model (see online supplementary appendix table S3).
Multiple imputation was performed in R V.3.1.2 (The R
Project for Statistical Computing, cran.r-project.org) and all
further statistical analyses were performed in Stata MP V.13
(Stata Corp, Texas, USA). Values of p<0.05 were considered to
be statistically signiﬁcant and all tests were two sided.
RESULTS
We identiﬁed 300 868 individuals with STEMI admitted to
hospitals in the UK. We excluded 23 332 (7.8%) records from
hospitals outside England, and 95 666 (34.5%) records for indi-
viduals in non-PPCI capable hospitals. Of the remaining
181 870 patients with a discharge diagnosis of STEMI, across
84 trusts, there were a total of 92 350 (50.8%) hospitalisations
314 Hall M, et al. Heart 2016;102:313–319. doi:10.1136/heartjnl-2015-308616
Healthcare delivery, economics and global health
for 90 489 patients for which PPCI was performed. There were
1859 (1%) patients who had multiple hospitalisations (ﬁgure 1).
The mean±SD age was 63.7±13.2 years; 26.4% of patients
were female and 14% had diabetes. Across the study years, the
mean age increased from 60.1 to 63.8 years (table 1). There was
a decrease in the proportion of patients belonging to the most
deprived group (56.7–22.4%), and a corresponding increase in
patients belonging to the least deprived group (3.3–18.4%).
Moreover, we found that the proportion of patients who
received PPCI and lived further away from the PPCI centre
increased from no cases living >30 km away in 2003/2004 to
18.3% of cases living >30 km away in 2011/2013. The median
number of trust beds remained stable over the study period
(843.5 in 2005/2007 to 837 in 2011/2013), while the mean
number of cardiologists increased (1.2 in 2005/2007 to 4.9 in
2011/2013). The number of trusts performing PPCI ‘24/7’
(24 h service 7 days a week) increased from 7.2% in 2005/2007
to 57% in 2011/2013.
Variation
There was an increase in the utilisation of PPCI over the
10 year study period, with the overall age and sex standardised
rate of PPCIs out of all STEMI hospitalisations increasing sig-
niﬁcantly from 0.01% (95% CI 0.001% to 0.06%) in 2003 to
86.3% (95% CI 79.5% to 94.2%) in 2013 (ﬁgure 2). On
average, there was a year-on-year increase in PPCI utilisation of
30% (IRR 1.30, 95% CI 1.23% to 1.36%) after adjustment for
patient and hospital characteristics. The rate of change varied
signiﬁcantly between hospitals (random effect parameter for
year SD=0.22, 95% CI 0.19 to 0.26). The rate of PPCI utilisa-
tion ranged from a 4% increase to a threefold increase (IRR
1.04, 95% CI 1.23 to 1.36; and IRR 3.17, 95% CI 1.23 to
1.36) for the central 95% of trusts. The rate of change varied
over the study period, with an annual increase in PPCI utilisa-
tion of 63% occurring in 2006/2008 (IRR 1.63, 95% CI 1.57
to 1.71) followed by a 9% increase in 2009/2011 (IRR 1.09,
95% CI 1.08 to 1.09) and no further increase in 2012/2013
(IRR 1.01, 95% CI 0.98 to 1.03).
Determinants of utilisation
There were signiﬁcant associations between PPCI utilisation and
year of procedure, age, previous myocardial infarction, angina,
PCI, chronic renal failure, heart failure, diabetes, cerebrovascular
disease, distance to hospital, number of hospital beds, number of
interventional cardiologists, number of visiting cardiologists, and
the availability of a 24/7 PPCI service (table 2). PPCI utilisation
was signiﬁcantly lower for patients with previous myocardial
infarction (IRR 0.95, 95% CI 0.93 to 0.98), heart failure (IRR
0.86, 95% CI 0.81 to 0.92), angina (IRR 0.96, 95% CI 0.94 to
0.98), diabetes (IRR 0.97, 95% CI 0.95 to 0.99), chronic renal
failure (IRR 0.89, 95% CI 0.85 to 0.94), cerebrovascular disease
(IRR 0.96, 95% CI 0.93 to 0.99), aged >80 years (IRR 0.87,
95% CI 0.85 to 0.90), and travel distances >30 km (IRR 0.95,
95% CI 0.93 to 0.98). PPCI utilisation was signiﬁcantly higher
for patients with previous PCI (IRR 1.09, 95% CI 1.05 to 1.12),
among trusts with >5 interventional cardiologists (IRR 1.30,
95% CI 1.25 to 1.34), more visiting cardiologists (1–5 consul-
tants: IRR 1.31, 95% 1.26 to 1.36; >6 consultants: IRR 1.42,
1.35 to 1.49), and a 24/7 service (IRR 2.69, 95% CI 2.58 to
2.81). Larger hospitals had lower rates of PPCI (>1000 vs <700
beds, IRR 0.92, 95% CI 0.88 to 0.97). We found that 49% of
the unexplained variation in PPCI utilisation was due to differ-
ences between trusts (ICC 0.49).
DISCUSSION
This is the ﬁrst patient-level single country analysis of the tem-
poral implementation of PPCI for the emergency management
of STEMI. Over a 10 year study period, we found evidence for
an 8 year implementation phase that achieved overall high rates
of PPCI per STEMI coverage across England. However, this
occurred after a lag of several years. At the end of the study
period we found persisting wide variation in rates of PPCI at
hospitals and evidence that older and sicker patients were less
likely to receive PPCI. While PPCI utilisation was signiﬁcantly
associated with patient-level and trust-level characteristics, one
half of the unexplained variation in PPCI utilisation was due to
between-hospital factors.
To date, international registry data have shown that imple-
mentation of reperfusion therapy for STEMI is insufﬁcient.
Earlier studies described how England differed from other
European countries, with much slower PPCI adoption,23 and
greater between provider variation in 30 day mortality.24 This
study adds more detail—revealing signiﬁcant provider variation
in emergency care. Our ﬁndings are surprising since the acute
treatment of STEMI in a healthcare setting of universal coverage
should result in low inequalities in access. Moreover, for STEMI
there is little controversy or ambiguity concerning the effective-
ness of PPCI (STEMI is more readily diagnosable than NSTEMI
and the majority of patients are hospitalised), and the demand
for hospitalisation and treatment of STEMI is closely
determined by its incidence.
Provider variation was large during the early PPCI implemen-
tation phase—with greater uniformity later. Such diffusion pat-
terns are seen where there is a rapid improvement in treatments
or where the range of treatment options has been
enhanced,8 9 13 25 as in the UK with the transition from ﬁbrin-
olysis to PPCI. Yet, we identiﬁed between-provider variation at
the end of the study, when across the health system the majority
of STEMI patients received PPCI. Following the implementation
phase, between-provider variation in guideline-indicated care
should be minimal, and is likely to impact directly on popula-
tion health outcomes.13 26
Variation in healthcare utilisation rates may reﬂect differences
in population need for healthcare—with more services needed
in areas of higher demand. Our study exploited rich and repre-
sentative population panel data including individual-level health
measures as well as socioeconomic background information, and
temporal and spatial population data. To the contrary, we found
PPCI rates were lower at hospitals with a higher proportion of
patients who were elderly, diabetic, and with chronic renal and
Figure 1 Consort diagram of exclusions of the Myocardial Ischaemia
National Audit Project (MINAP) dataset. PPCI, primary percutaneous
coronary angiography; ST, ST-elevation myocardial infarction.
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heart failure. This ‘risk-treatment paradox’ has been described
for other cardiovascular diseases and contrasts with the absolute
risk of a life-threatening complication from an evidence based
therapy being unlikely to exceed the survival beneﬁt when
applied in high-risk populations.27 28 Utilisation of PPCI did
not appear to be inﬂuenced by area deprivation.
While age and comorbid status contributed to PPCI utilisa-
tion, almost half of the unexplained variation in PPCI use was
at the hospital level. Supply factors, such as numbers of cardi-
ologists and availability of a 24 h, 7-days-a-week PPCI service
were strong determinants of PPCI utilisation. Others have also
shown that provider variation is mainly associated with the
Table 1 Patient characteristics by period of admissions to hospital in England, 2003–2013
Patient demographics, history
and cardiac status
Period of admission to hospital
Total (n=90 498) 2003–2004 (n=30) 2005–2007 (n=4299) 2008–2010 (n=35 000) 2011–2013 (n=51 169)
Age, years 63.7 (13.2) 60.1 (13.2) 63.0 (13.0) 63.6 (13.2) 63.8 (13.2)
Female 23 776 (26.4) 7 (23.3) 1119 (26.1) 9286 (26.6) 13 364 (26.3)
Ethnicity
Caucasian 71 631 (90.0) 17 (77.3) 2999 (83.2) 27 241 (90.6) 41 374 (90.2)
Other 7941 (10.0) 5 (22.7) 714 (16.8) 2836 (9.4) 4496 (9.8)
Deprivation (IMD)
1 (Least deprived) 15 368 (17.3) 1 (3.3) 550 (13.2) 5587 (16.2) 9230 (18.4)
2 16 250 (18.3) 1 (3.3) 625 (15.0) 6014 (17.5) 9610 (19.1)
3 17 730 (19.9) 3 (10.0) 797 (19.1) 6675 (19.4) 10 255 (20.4)
4 18 031 (20.3) 8 (26.7) 952 (22.8) 7180 (20.8) 9891 (19.7)
5 (Most deprived) 21 556 (24.2) 17 (56.7) 1258 (30.1) 9007 (26.1) 11 274 (22.4)
Ever smoked 33 240 (66.9) 13 (82.6) 1630 (67.1) 12 920 (67.5) 18 677 (66.4)
Diabetes 11 580 (14.0) 4 (13.8) 593 (14.4) 4188 (13.2) 6795 (14.5)
Hypertension 33 645 (42.9) 10 (90.9) 1672 (46.7) 12 883 (43.6) 19 080 (42.2)
Dyslipidaemia 25 195 (33.0) 11 (91.7) 1249 (36.9) 9826 (34.3) 14 109 (31.9)
Family history of CAD 25 885 (36.9) 0 11 221 (39.4) 10 328 (39.1) 14 336 (35.2)
Previous angina 9683 (12.6) 0 510 (15.1) 4047 (13.9) 5126 (11.5)
Previous MI 9507 (6.7) 2 (6.7) 500 (13.2) 3799 (12.8) 5255 (11.7)
Previous PCI 5933 (7.6) 1 (3.3) 299 (7.9) 2320 (7.9) 3313 (7.4)
Previous CABG 1877 (2.4) 1 (3.3) 97 (2.5) 754 (2.6) 1025 (2.3)
Chronic heart failure 995 (1.3) 0 60 (1.8) 336 (1.2) 599 (1.3)
Cerebrovascular disease 3492 (4.6) 2 (66.7) 147 (4.4) 1353 (4.7) 1990 (4.5)
Renal failure 1607 (2.1) 0 81 (2.4) 644 (2.2) 882 (2.0)
Peripheral vascular disease 2195 (2.9) 3 (75.0) 123 (3.8) 830 (2.9) 1239 (2.8)
Chronic lung disease 8068 (10.5) 0 342 (10.5) 3030 (10.5) 4696 (10.5)
Distance to hospital in km
0–5 17 421 (19.6) 10 (33.3) 1449 (34.8) 7535 (21.9) 8427 (16.8)
6–15 33 321 (37.4) 19 (63.4) 1829 (43.9) 13 942 (40.4) 17 531 (34.9)
16–29 24 060 (27.0) 1 (3.3) 596 (14.3) 8330 (24.2) 15 133 (30.1)
+30 14 189 (15.9) 0 294 (7.1) 4686 (13.6) 9209 (18.3)
Trust characteristics (n=84)
Total number of beds
<700 214 (31.4) – 69 (31.1) 74 (32.2) 71 (30.9)
700–999 246 (36.1) – 79 (35.6) 78 (33.9) 89 (38.7)
≥1000 222 (32.5) – 74 (33.3) 78 (33.9) 70 (30.4)
Number of acute and general beds
<700 292 (43.7) – 112 (51.4) 89 (39.9) 91 (39.9)
700–999 216 (32.3) – 60 (27.5) 71 (31.8) 85 (37.3)
≥1000 161 (24.1) – 46 (21.0) 63 (28.3) 52 (22.8)
Number of in-house interventional cardiologists
None 208 (28.8) – 178 (75.7) 24 (9.8) 6 (2.5)
1–5 320 (44.4) – 39 (16.6) 144 (59.0) 137 (56.6)
>5 193 (26.8) – 18 (7.7) 76 (31.2) 99 (40.9)
Number of visiting interventional cardiologists
None 432 (59.9) – 203 (86.4) 124 (50.8) 105 (43.4)
1–5 199 (27.6) – 21 (8.9) 80 (32.8) 98 (40.5)
>5 90 (12.5) – 11 (4.7) 40 (16.4) 39 (16.1)
24/7 PPCI service 261 (36.2) – 17 (7.2) 106 (43.4) 138 (57.0)
Teaching status 327 (45.4) – 107 (45.5) 110 (45.1) 110 (45.5)
CABG, coronary artery bypass graft surgery; CAD, coronary artery disease; IMD, index of multiple deprivation; MI, myocardial infarction; PCI, percutaneous coronary intervention; PPCI,
primary PCI.
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medical care systems and less with regional differences in
disease incidence.25 Since PPCI is highly dependent on the
availability of specialist resources, our ﬁndings are not surpris-
ing.29 30 Notably the regulation of specialist capacity to
perform medical procedures, with the availability of catheter-
isation laboratories (supplier-induced demand), is a strong
determinant of technology use.8 9 29 Our study reveals that
universal healthcare coverage and evidence for the beneﬁts of
a new technology associated with signiﬁcant improvements in
care for a wide sector of the population does not guarantee
similar utilisation rates for treatment across a nation. Indeed,
our observation of between-trust variation in PPCI use suggests
an opportunity to further increase the utilisation of PPCI ser-
vices and, ultimately, reduce premature cardiovascular deaths.
This is particularly pertinent as, a priori, national implementa-
tion of PPCI across the NHS was based on a Department of
Health directive and funding aiming for equitable PPCI
Figure 2 Observed and ﬁtted average rate of primary percutaneous
coronary intervention (PPCI) in England from 2003 to 2013.
Table 2 Unadjusted and adjusted IRRs with 95% CIs assessing variation in utilisation of PPCI in England, 2003–2013
Unadjusted Adjusted
IRR (95% CI) p Value IRR (95% CI) p Value
Year 1.28 (1.27 to 1.28) <0.001 1.30 (1.23 to 1.36) <0.001
Age
<55 Ref Ref
55–64 0.97 (0.96 to 0.99) <0.001 1.00 (0.98 to 1.01) 0.731
65–79 0.93 (0.92 to 0.95) <0.001 0.99 (0.97 to 1.01) 0.117
80+ 0.83 (0.81 to 0.85) <0.001 0.87 (0.85 to 0.90) <0.001
Male gender 1.06 (1.05 to 1.08) <0.001 1.02 (1.00 to 1.03) 0.044
Distance to hospital in km
<6 Ref Ref
6–15 1.15 (1.13 to 1.18) <0.001 1.02 (0.99 to 1.04) 0.078
16–29 1.32 (1.28 to 1.35) <0.001 1.03 (1.00 to 1.05) 0.025
30+ 1.28 (1.25 to 1.32) <0.001 0.95 (0.93 to 0.98) 0.001
Family history of chronic heart disease 1.21 (1.19 to 1.23) <0.001 1.01 (1.00 to 1.03) 0.085
Previous acute MI 0.92 (0.90 to 0.94) <0.001 0.95 (0.93 to 0.98) <0.001
Previous chronic cardiac failure 0.76 (0.72 to 0.81) <0.001 0.86 (0.81 to 0.92) <0.001
Previous angina 0.86 (0.84 to 0.88) <0.001 0.96 (0.94 to 0.98) 0.001
Diabetes mellitus 1.00 (0.98 to 1.02) 0.860 0.97 (0.95 to 0.99) 0.001
Chronic renal failure 0.90 (0.86 to 0.95) <0.001 0.89 (0.85 to 0.94) <0.001
Previous PCI 1.11 (1.09 to 1.14) <0.001 1.09 (1.05 to 1.12) <0.001
Previous CABG 0.93 (0.89 to 0.97) <0.001 0.96 (0.92 to 1.01) 0.130
Cerebrovascular disease 0.94 (0.91 to 0.97) <0.001 0.96 (0.93 to 0.99) 0.012
Smoker 1.04 (1.03 to 1.06) <0.001 1.01 (0.99 to 1.02) 0.205
Total number of beds at trust
<700 Ref Ref
700–999 0.93 (0.89 to 0.98) 0.003 0.99 (0.95 to 1.04) 0.802
1000+ 0.75 (0.71 to 0.79) <0.001 0.92 (0.88 to 0.97) 0.001
Number of interventional cardiologists
<5 Ref Ref
>5 4.10 (4.00 to 4.21) <0.001 1.30 (1.25 to 1.34) <0.001
Number of visiting interventional cardiologists
0 Ref Ref
1–5 3.46 (3.37 to 3.56) <0.001 1.31 (1.26 to 1.36) <0.001
6+ 4.22 (4.09 to 437) <0.001 1.42 (1.35 to 1.49) <0.001
PPCI service
Daytime only (09:00–17:00) Ref Ref
24 h service 7 days a week 7.19 (6.99 to 7.39) <0.001 2.69 (2.58 to 2.81) <0.001
Teaching status (university hospital) 1.27 (1.19 to 1.36) <0.001 1.01 (0.93 to 1.10) 0.809
CABG, coronary artery bypass graft surgery; IMD, index of multiple deprivation; IRR, incidence rate ratio; MI, myocardial infarction; PCI, percutaneous coronary intervention; PPCI,
primary PCI.
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delivery across hospital trusts. To address this shortfall, our
ﬁndings provide evidence to suggest that PPCI-capable hospi-
tals must have an ‘all-comers’ policy that is compliant with
clinical guidelines, provide a 24 h, 7-days-a-week service, be
adequately staffed with specialists, and not be so large that
there are diseconomies of scale. Future research is needed to
ascertain whether the availability of specialist facilities and
regulation of capacity explains the large and signiﬁcant
between-hospital variation which was not attributable to case
mix and stafﬁng levels.
Limitations
This study analysed patient-level data aiming speciﬁcally to not
introduce an ecological fallacy; it does, however, have limita-
tions. While MINAP data entry is subject to routine error check-
ing and a mandatory annual data validation exercise, the analyses
were dependent upon the accuracy of the data. We were unable
to include patients in non-PPCI capable hospitals, within which
we identiﬁed a small proportion of patients who did receive
PPCI (n=8862; 9%). We controlled for a number of patient risk
factors deemed clinically relevant, which are assumed to be
exogenous to the hospital, and can be derived from MINAP.
However, we do not claim that this set of control variables is
exhaustive and the issues of additional confounding are appar-
ent. Even so, a strength of our study is that we used detailed
registry data to control for patients’ comorbid conditions, thus
making our inferences more robust than using routinely available
administrative or survey sample data. Finally, observational ana-
lyses such as these reveal important associations, but cannot
prove causation.
Conclusions
This nationwide 10 year study of the uptake and utilisation of
PPCI for STEMI found evidence for an 8 year implementation
phase that achieved overall high rates of PPCI per STEMI
hospitalisation. However, at the end of the implementation
phase, there remained wide variation in hospital rates of PPCI.
In particular, older and sicker patients were less likely to receive
PPCI. While the use of PPCI was signiﬁcantly associated with
patient-level characteristics, there remained signiﬁcant variation
due to hospital-speciﬁc factors that were not attributable to
differences in medical stafﬁng levels. Compliance with agreed
clinical pathways for patients presenting with STEMI is needed
to ensure more equitable quality of care.
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Key messages
What is already known on this subject?
▸ ST-elevation myocardial infarction (STEMI) is a common and
major cause of premature death. Timely primary
percutaneous intervention (PPCI) is the preferred mode of
revascularisation because it is associated with signiﬁcantly
improved outcomes.
▸ There is variation in the level of use of PPCI which is
associated with supply and demand factors, but this has not
been investigated at the level of the provider using
patient-level data within a single healthcare system.
What might this study add?
▸ While the rates of PPCI increased rapidly (0.01% to 86.3%),
the entire implementation took 8 years. Sicker patients were
less likely to receive PPCI by 5%, 4% and 3% for those with
previous myocardial infarction, angina and diabetes,
respectively. We found evidence for wide variation between
hospitals in their utilisation of PPCI, and although medical
stafﬁng levels were associated with this variation, it did not
account for all of the between-hospital variation.
How might this impact on clinical practice?
▸ Our observation of between-trust variation in PPCI use
suggests an opportunity to further increase the utilisation of
PPCI services and, ultimately, reduce premature
cardiovascular deaths. Compliance with agreed clinical
pathways for patients presenting with STEMI is needed to
ensure more equitable quality of care.
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